Structures of ADP-ribosylated rifampicin and its metabolite:: Intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756

被引：14

作者：

Morisaki, N

Hashimoto, Y

Furihata, K

Imai, T

Watanabe, K

Mikami, Y

Yazawa, K

Ando, A

Nagata, Y

Dabbs, ER

机构：

[1] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan

[2] Univ Tokyo, Div Agr & Agr Life Sci, Bunkyo Ku, Tokyo 1138657, Japan

[3] Chiba Univ, Res Ctr Pathogen Fungi & Microbial Toxicoses, Chuo Ku, Chiba 2608673, Japan

[4] Chiba Univ, Grad Sch Sci & Technol, Dept Biotechnol, Inage Ku, Chiba 2718510, Japan

[5] Univ Witwatersrand, Dept Mol & Cell Biol, Johannesburg, South Africa

来源：

JOURNAL OF ANTIBIOTICS | 2000年 / 53卷 / 03期

关键词：

D O I：

10.7164/antibiotics.53.269

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

23-(O-ADP-Ribosyl)rifampicin [RIP-TAs (3, Na+ form), RIP-TAf (4, H+ form)] was obtained as an intermediate in the conversion process of rifampicin (1) to RIP-Mb (2) that is mediated by cell homogenates of Mycobacterium smegmatis DSM43756 or of Escherichia coli carrying a mycobacterial mono(ADP-ribosyl) transferase gene, in the presence of NADH. 23-[O-(5'-Phosphoribosyl)] rifampicin (5, RIP-TAp) was also obtained by the reaction of rifampicin with NADH in the presence of a homogenate of M. smegmatis. The structures of 3, 4, and 5 were determined by means of MS and NMR analyses.

引用

页码：269 / 275

页数：7

共 20 条

[1]

ANDERSEN SJ, 1991, FEMS MICROBIOL LETT, V79, P247, DOI 10.1016/0378-1097(91)90093-P

[2] C-13 NUCLEAR-MAGNETIC-RESONANCE STUDY OF ENZYME COFACTOR FLAVIN-ADENINE DINUCLEOTIDE [J].

BREITMAIER, E ;

VOELTER, W .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1972, 31 (02) :234-+

[3] RIFAMPICIN INACTIVATION BY BACILLUS SPECIES [J].

DABBS, ER ;

YAZAWA, K ;

TANAKA, Y ;

MIKAMI, Y ;

MIYAJI, M ;

ANDERSEN, SJ ;

MORISAKI, N ;

IWASAKI, S ;

SHIDA, O ;

TAKAGI, H ;

KADOWAKI, K .

JOURNAL OF ANTIBIOTICS, 1995, 48 (08) :815-819

[4] RIBOSYLATION BY MYCOBACTERIAL STRAINS AS A NEW MECHANISM OF RIFAMPIN INACTIVATION [J].

DABBS, ER ;

YAZAWA, K ;

MIKAMI, Y ;

MIYAJI, M ;

MORISAKI, N ;

IWASAKI, S ;

FURIHATA, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :1007-1009

[5] RIFAMPICIN INACTIVATION BY RHODOCOCCUS AND MYCOBACTERIUM SPECIES [J].

DABBS, ER .

FEMS MICROBIOLOGY LETTERS, 1987, 44 (03) :395-399

[6]

FURESZ S, 1970, ANTIBIOT CHEMOTHER, V16, P316

[7] Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis [J].

Imai, T ;

Watanabe, K ;

Mikami, Y ;

Yazawa, K ;

Ando, A ;

Nagata, Y ;

Morisaki, N ;

Hashimoto, Y ;

Furihata, K ;

Dabbs, ER .

MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1999, 5 (04) :259-264

[8]

Lancini G, 1977, STRUCTURE ACTIVITY R, P531

[9] RIFAMPICIN - A NEW ORALLY ACTIVE RIFAMYCIN [J].

MAGGI, N ;

PASQUALUCCI, CR ;

BALLOTTA, R ;

SENSI, P .

CHEMOTHERAPY, 1966, 11 (05) :285-+

[10] INTERACTION OF INTERFERON GAMMA AND CPT-11, A NEW DERIVATIVE OF CAMPTOTHECIN, IN HUMAN ENDOMETRIAL CARCINOMA CELL-LINES [J].

MORI, H ;

SAWAIRI, M ;

NIWA, K ;

ITOH, N ;

HANABAYASHI, T ;

KONDOH, H ;

TAMAYA, T .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1993, 3 (01) :36-43

← 1 2 →